Cytek Biosciences, Inc. Common Stock (CTKB) is a publicly traded Healthcare sector company. As of May 21, 2026, CTKB trades at $3.77 with a market cap of $458.46M and a P/E ratio of 0.00. CTKB moved +5.88% today. Year to date, CTKB is -27.64%; over the trailing twelve months it is +41.73%. Its 52-week range spans $2.37 to $7.63. Analyst consensus is buy with an average price target of $5.34. Rallies surfaces CTKB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own CTKB include Centerbook Partners and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cytek Biosciences, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $3.77 |
| Market Cap | $458.46M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.63 |
| 52-Week Low | $2.37 |
| Volume | 105 |
| Avg Volume | 0 |
| Revenue (TTM) | $204.17M |
| Net Income | $-74.00M |
| Gross Margin | 51.70% |
4 analysts cover CTKB: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.34.